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Recombinant Adeno-Associated Viral Integration and Genotoxicity:
Insights from Animal Models
Randy J. Chandler,1 Mark S. Sands,2,3,* and Charles P. Venditti1,*
1Medical Genomics and Metabolic Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Department of Health and Human
Services, Bethesda, Maryland; Departments of 2Internal Medicine and 3Genetics, Washington University School of Medicine, St. Louis, Missouri.
Currently, clinical gene therapy is experiencing a renaissance, with new products for clinical use approved
in Europe and clinical trials for multiple diseases reporting positive results, especially those using re-
combinant adeno-associated viral (rAAV) vectors. Amid this new success, it is prudent to recall that the
field of gene therapy experienced tragic setbacks in 1999 and 2002 because of the serious adverse events
related to retroviral and adenoviral gene delivery in two clinical trials that resulted in the death of two
patients. In both cases, the toxicity observed in humans had been documented to occur in animal models.
However, these toxicities were either undetected or underappreciated before they arose in humans. rAAVs
have been tested extensively in animals and animal models of disease, largely without adverse events,
except for transient elevation in liver enzymes in some patients. However, a small but growing number of
murine studies have documented that adeno-associated viral gene delivery can result in insertional
mutagenesis. Herein, the aggregate data are reviewed from multiple murine studies where genotoxicity
associated with rAAV treatment has been observed. The data emphasize the need for a proactive position
to evaluate the potential risks and possible solutions associated with AAV-mediated gene therapy.
Keywords: AAV, gene therapy, insertional mutagenesis, genotoxicity, cancer, HCC.
INTRODUCTION
THE CURRENT LEVEL OF ENTHUSIASM for gene ther-
apy as a viable therapeutic approach to treat a
variety of human diseases is unprecedented. No
longer is gene therapy a largely academic under-
taking as biotechs, pharma companies, venture
capitalists, and investors become increasingly
more involved in the field.1–3 However, after two
highly publicized deaths occurring in two sepa-
rate gene therapy clinical trials in the late 1990s
and early 2000s, the future of gene therapy ap-
peared bleak.4,5 The toxicity observed in these
clinical trials was caused by immunogenicity to an
adenoviral vector and then to insertional muta-
genesis by a retroviral vector. These types of
toxicities had been observed in animals,6,7 but the
risk in humans was deemed to be minimal. Cur-
rent viral vectors are designed to be less mutage-
netic, as in the case of SIN lentiviruses, or are
intrinsically less immunogenic than the those
that caused severe adverse events in earlier clin-
ical trials.
One such vector, recombinant adeno-associated
virus (rAAV), is inherently non-pathogenic and
less likely to result in insertional mutagenesis
because the majority of vector genomes remain
episomal after transduction.8,9 This viral vector is
suitable for both localized and systemic gene de-
livery and is capable of transducing a variety of
cell types. To date, numerous naturally occurring
AAV serotypes have been isolated from a number of
different species, and novel capsids have been ge-
netically engineered.10 A number of rAAVs have
been shown to exhibit tropisms for hepatocytes,
myocytes, and neuronal cells.
AAV has several advantages over other com-
monly used viral vectors that have been adapted
for gene delivery, such as retroviral, lentiviral, and
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adenoviral vectors, including an ability to trans-
duce dividing and nondividing cells, highly efficient
in vivo cell transduction, sustained transgene ex-
pression, tropisms for specific tissues and cell types,
low immunogenicity, and a history of clinical safety.
The rAAVs have been successfully used as gene
delivery vehicles in numerous animal models of
human disease and have yielded long-term trans-
gene expression without apparent vector-related
toxicity. Furthermore, clinical trials using rAAV
have involved hundreds of subjects, supporting the
safety of these vectors for use in humans.11,12
The rAAVs used in gene delivery are physically
different and exhibit different characteristics rela-
tive to the wild-type AAV precursor (reviewed by
Daya and Berns13). The life cycle of wild-type AAV
includes both latent and lytic phases. The AAV ge-
nome is 4.7 kb in size and consists of three promoters
and multiple open reading frames coding for the
replication proteins (Rep), the capsid proteins (Cap),
and assembly-activating protein (AAP), which are
flanked by inverted terminal repeats (ITR). The ITRs
are DNA elements that are 145 bp in length and that
are integral to AAV genome replication and proper
DNA encapsulation.14–16 During the latent stage, the
AAV2 provirus preferential integrates into a specific
location on human chromosome 19.17–19
The wild-type AAV genome is substantially al-
tered to create the rAAV genome used in gene
therapy, and these alterations result in dramatic
differences in physical characteristics between the
wild-type AAV and rAAV. When rAAVs are ge-
netically engineered to carry exogenous sequences,
such as enhancers, promoters, transgenes, and
polyA signals, most of the wild-type AAV genome is
removed because AAVs have a packaging con-
straint of approximately 4.7 kb. While the Rep and
Cap proteins are necessary for rAAV production,
the AAV ITRs are the only sequences necessary for
rAAV packaging of the regulatory and transgene
sequences.20 Hence, rAAV integration into the host
genome is predicted to be greatly reduced because
the sequences coding for the native AAV proteins
needed for integration are not present in the re-
combinant AAV. However, a low number of random
integrations do occur following gene delivery using
rAAV.21 The rAAV vectors’ reduced ability to in-
tegrate also means that the therapeutic transgene
exists predominantly in the host cell nucleus as
non-replicating episomes. Because rAAV largely
does not integrate, vector genomes and transgene
expression are lost over time because of the in-
ability to replicate with the host cell’s DNA.22
Unlike adenoviral and gamma-retroviral vec-
tors, rAAV has been used in numerous clinical
trials with no vector- or viral-related severe ad-
verse events, other than transient transaminitis.23
A gene therapy pilot safety study using an adeno-
virus to treat a patient with ornithine transcarba-
mylase deficiency resulted in a fatality thought to
be the result of a systemic inflammatory response
to the adenoviral capsid.24 This type of severe ad-
verse immune response has not been observed in
clinical trials that utilize rAAV gene therapy, pre-
sumably because AAV is less immunogenic than
adenovirus.25,26 In fact, only mild elevations of li-
ver enzymes have been reported after systemic
rAAV delivery in patients.23,27 Clinical trials that
utilized gamma-retroviral mediated ex vivo gene
transfer to treat X-linked severe combined im-
munodeficiency and Wiskott–Aldrich syndrome
have reported insertional mutagenesis by the gene
therapy vector, which caused leukemia in pa-
tients.28,29 Because the rAAV transgene exists in a
predominately episomal state and integrates at a
very low frequency following rAAV transduction,
the chances of insertional mutagenesis by a rAAV
transgene are greatly reduced in comparison with
retroviral and lentiviral vectors, which usually in-
tegrate into the host genome. However, an in-
creased incidence in hepatic carcinoma (HCC) in
mice after rAAV gene delivery has been reported,
and some of these studies have shown that inser-
tional mutagenesis by rAAV was the most likely
cause of the HCC. Herein, some of the studies, lis-
ted in Table 1, that observed or interrogated HCC
formation after rAAV gene delivery are discussed.
The key observations from each study are high-
lighted, and unresolved issues are discussed.
AAV AND HCC: AN OVERVIEW
OF PUBLISHED STUDIES
Lysosomal storage diseases (LSDs) are a rela-
tively large class of inherited metabolic disease
that are typically caused by a deficiency in a sol-
uble lysosomal enzyme.30 LSDs are ideal candi-
dates for systemic gene therapy.31 They are simple,
monogenic diseases, and some proportion of lyso-
somal enzymes can be secreted from corrected cells
and taken up by distant cells through a receptor-
mediated process known as cross-correction.32
Mucopolysaccharidosis type VII (MPSVII) is an in-
variably fatal LSD caused by a deficiency in
the lysosomal enzyme, b-glucuronidase (GUSB).33
b-Glucuronidase is ubiquitously expressed, and its
deficiency leads to the accumulation of undegraded
glycosaminoglycans in most tissues, including the
liver spleen, heart, kidney, bones, eyes, and brain. A
spontaneously arising mouse mutant was discovered
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at The Jackson Laboratory that has a single base
pair deletion in the Gusb gene, is completely defi-
cient in Gusb activity, and mimics most of the bio-
chemical, histological, and clinical features of human
MPSVII.34,35 The MPSVII mouse has been used ex-
tensively in preclinical studies to determine the effi-
cacy of enzyme replacement therapy, stem cell–
mediated therapy, and gene replacement therapy.
One of the first systemic AAV-mediated gene
therapy experiments was performed using MPSVII
mice.36,37 Intravenous injection of a first-generation
AAV2 vector into newborn MPSVII mice resulted
in widespread transduction, relatively high levels
of human GUSB activity, and prevention of lyso-
somal storage material in most tissues of the body,
including the brain. A follow-up study in the MPSVII
mice showed that this approach led to persistent
GUSB expression and resulted in dramatic improve-
ments in bone development, retinal function, auditory
function, body weight, and life-span.38 However, it
was discovered that a number of long-lived (‡1
year) rAAV-treated MPSVII mice from this study
developed HCC.39 It was virtually impossible to
determine the cause of the tumors in that study,
since the experiment was not designed as a toxicity
study, and the number of animals with HCC was
relatively small. In addition, the tumor samples
were negative for GUSB activity, and the rAAV
genome could not be detected by polymerase
chain reaction (PCR) using primers specific for
the GUSB cDNA.
A larger follow-up study in newborn MPSVII and
normal mice was performed in an attempt to rep-
licate the findings of Donsante et al. and to deter-
mine the cause of the HCC. Intravenous injection of
the same AAV2 vector resulted in 30–60% of both
normal and MPSVII mice developing HCC at ‡13
months of age.40 It was also shown that the inci-
dence of HCC in long-lived MPSVII mice receiving
bone-marrow transplantation and a transgenic
mouse expressing *20-fold greater than normal
levels of GUSB was nearly zero. The most striking
and unexpected finding was that four of the six
tumors evaluated had the recombinant AAV vector
integrated within a 6,000 bp region of the Rian lo-
cus on mouse chromosome 12. This region contains
several genes and is rich in micro- and snoRNAs.
Integration of the rAAV vector dysregulated this
locus. Another interesting finding was that all of
the integrants were rearranged such that the
GUSB cDNA was deleted. This explains the lack of
a PCR product and absent GUSB activity in the
tumors examined in the original report.39
Although rAAV integration into the Rian locus
was associated with the development of HCC, aTa
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cause and effect relationship was suggested but not
proven. However, a subsequent study showed that
there was a high frequency of integration into the
same locus following intravenous injection of an
rAAV vector containing a promoter and enhancer
combination (no transgene) flanked by sequences
that are homologous to the Rian locus.41 Inte-
gration of the promoter/enhancer elements and
subsequent dysregulation of this locus led to
nearly 100% penetrance of the HCC phenotype.
These data strongly suggest that disruption of this
locus by integration of an rAAV vector containing
a strong promoter/enhancer combination causes
HCC in mice.
The development of HCC following intravenous
injection of an AAV vector was still generally con-
sidered an isolated event, even though there were
several additional reports of tumorigenesis fol-
lowing rAAV administration. Portal-vein injection
of an rAAV vector containing the woodchuck hep-
atitis virus post-transcriptional regulatory ele-
ment and the phenylalanine hydroxylase cDNA
into the mouse model of phenylketonuria also re-
sulted in a high frequency of HCC.42 The authors of
this report concluded that the HCC was caused
by expression of the hepatitis virus protein X-
phenylalanine hydroxylase fusion protein. Al-
though immunohistochemical analysis showed
that the hepatitis virus protein X-phenylalanine
hydroxylase fusion protein was expressed in the
liver of experimental animals, the expression ap-
peared to be limited to the normal liver tissue and
not the tumor. In retrospect, these data suggest
that the tumors were not caused by expression of
the hepatitis virus protein X-phenylalanine hy-
droxylase fusion protein, rather a potential inte-
gration of a rearranged rAAV vector that did not
express the transgene, but manifested genotoxicity
similar to what was seen with the MPSVII mice
and vectors.
A high incidence of HCC was also observed in
ornithine transcarbamolase (OTC)-deficient mice
following portal-vein injection of rAAV vectors en-
coding either OTC or LacZ.43 OTC-deficient mice
are known to have a high incidence of spontaneous
liver tumors. Statistical analyses of the various
groups suggested that mice treated with the LacZ
vector had an increased risk of HCC. A retrospec-
tive analysis of some of the samples from this study
discovered numerous integration sites in the tumor
tissue, including integrations into the Rian locus.44
There is also evidence suggesting that systemic
delivery of rAAV vectors does not lead to the de-
velopment of HCC. In 2005, a large retrospective
study of mice treated with rAAV did not find an
association between rAAV treatment and HCC in
mice.45 A second, relatively large study, involving
132 mice, specifically designed to address the is-
sue of HCC following intravenous administration
of rAAV vectors, showed no statistically significant
increase in HCC in mice injected with an rAAV
vector encoding clotting factor IX.46 However, the
small number of HCCs observed in this study, five
in total, four of which occurred in the rAAV-treated
group, may not have been sufficient to detect a
significant association. Nevertheless, this study
also used integration profiling and gene expression
analysis to demonstrate that the HCCs appeared
free of clonal integration events, or gene expression
changes related to rAAV integration.46 A separate
study showed that hepatic tumors were observed in
young adult mice following intravenous injection of
a high dose (2 · 1010 vp/mouse) of an rAAV vector
expressing a factor IX cDNA containing the Padua
mutation, but occurred at an insignificant rate of
*15%. Genomic characterization was not per-
formed on the HCC in this study. One significant
difference between studies has been the develop-
mental timing of the injections. Donsante et al.
injected the mice on postnatal day (PND) 1–2; Bell
et al. and Li et al. injected young adult ani-
mals.39,45,46 These data suggest that mice injected
during the newborn period may be more suscepti-
ble to the development of rAAV-associated HCC
and, furthermore, that the HCC association was
not mouse model dependent.
In a complex study using varied scAAV vectors,
applied with and without the agent camptothecin,
and/or partial hepatectomy, Rosas et al. assayed
HCC formation in cancer-prone and immunodefi-
cient mice, with the intention that genotoxic ef-
fects of rAAV may be magnified.48 While the
authors did observe HCC formation, and even in-
tegration events into cellular oncogenes, the very
high background rate of HCC formation and rela-
tively low number of recovered integration events
failed to resolve whether rAAV was carcinogenic.
The next set of studies confirmed what was ini-
tially observed by Donsante et al., specifically that
mice treated in the neonatal period with high doses
of rAAV had a tendency to develop HCCs later in
life. As with earlier studies that have observed
HCC after rAAV administration, the most recent
studies were designed to assess efficacy not toxicity
in mouse models of either Sandhoff disease (SD) or
methylmalonic acidemia (MMA). In the case of SD,
neonatal mice were injected via the superficial
temporal vein with a relatively high dose (2.5 · 1014
vg/kg) of an rAAV9 vector that used the CMV pro-
moter to drive the expression of the HEXB cDNA,
RAAV INTEGRATION AND GENOTOXICITY 317
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and followed for beneficial effects.49 At the experi-
mental end point of 43 weeks, gross examination
during necropsy revealed tumors in 8/10 neona-
tally rAAV9-HexB–injected control and SD mice;
seven animals had liver tumors, and one had
multiple lung tumors. Tumors were not observed in
untreated mice, but it should be noted that un-
treated SD mice uniformly perished, typically by 15
weeks of age. In 2/7 of the liver tumors, integra-
tions into the Rian locus were observed, while the
single mouse that developed lung cancer was found
to have an rAAV integration in fibroblast growth
factor receptor 2 (Fgfr2), a gene known to have al-
tered expression in cancer. Although this study
lacked large numbers of control animals, the pen-
etrance of HCC in the mice treated as neonates
clearly implicates rAAV therapy as a predisposing
factor to carcinogenesis.
The recent report by Chandler et al. is the larg-
est mouse study to report rAAV genotoxicity to
date. It used large numbers of mice that were
treated with a variety of rAAV vectors and sero-
types, or that were untreated.50 In this study, the
colony-background incidence of HCC measured at
<10% (n = 51 mice), whereas control (n = 24) and
MMA mice (n = 24) treated in the neonatal period
with a dose of 1 · 1011 vg/pup of therapeutic or re-
porter rAAVs developed HCC at a rate of 50–75%
by 2 years of age. This study confirmed the findings
of several previous reports that identified clonal
rAAV integrations in the Rian locus, with upre-
gulation of proximally located micro-RNAs and
genes as the likely cause of the HCC. Identifying
insertional mutagenesis of the Rian locus as the
cause of HCC was not a surprising finding because
previous studies to identify genes involved in car-
cinogenesis have identified mutations in the Rian
locus as a cause of HCC in mice.51,52
This study also reported several unique findings
with regard to rAAV toxicity and integration pat-
terns. First, the risk of the HCC was found to be
rAAV dose-dependent. Second, a majority of the
causative HCC-rAAV integrations were mapped to
Mir341, a locus within Rian. As depicted in Fig. 1A, a
genomic alignment centered on Mir341 revealed
several unusual features. The locus appears only to
be present in rodents, and contains an embedded
repeat. Upon closer inspection, this repeat contains a
unique array of two simple quadranucleotide repeats
(CCGT and GGCT), some of which are internally
repeated, as well as 11 CpG dinucleotides, yet is
flanked by conserved sequences (Fig. 1B). Most rAAV
Figure 1. (Continued)
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HCC integrations mapped into this tiny microRNA,
and perhaps most importantly, one rAAV, which
utilized an hAAT promoter and synthetic MUT allele
(designated synMUT in the Fig. 1B), did not cause
upregulation of proximally located miRNAs and
genes or HCC, suggesting that rAAV vector design
could influence genotoxicity.
The use of a sensitive integration-capture method
that relied on high throughput sequencing (HTS)
allowed for the detection of thousands of rAAV in-
tegration events from approximately 40 samples has
afforded a limited assessment of integration prefer-
ences.50 To query integration preferences in a very
direct fashion, the number of integrations in a locus
was divided by the size of the locus as measured in
base pairs in order to normalize for frequency. Ap-
proximately 149 of a total of 1,205 loci with an rAAV
integration had multiple rAAV integrations (Sup-
plementary Table S1; Supplementary Data are
available online at www.liebertpub.com/hum). Ta-
ble 2 shows the loci with the highest rAAV integra-
tion frequency, which ranges from 2.19 · 10-1 to
4.40 · 10-7 integrations per base pair. Of importance,
and in contrast to previous studies that have sug-
gested the rAAV integration is largely random, it is
noted that rAAV integration frequencies varied sig-
nificantly between different loci, suggesting an in-
tegration preference by rAAV (Table 2) not yet
observed in smaller rAAV data sets. This analysis
also suggests that the characterization of many more
integration events will be needed to further define
sites preferred for integration by rAAV.
CONCLUDING REMARKS
AND FUTURE DIRECTIONS
Given the recent observation that AAV integra-
tions appear to be present in some human HCCs
and, in subset, may be pathologically relevant, a
careful reconsideration of possible genotoxicity me-
diated by rAAV in preclinical models is warranted as
vectors are studied before entering the clinic.53 What
is clear from a number of reports is that mice treated
in the neonatal period with high doses of rAAV
that contains strong promoter-enhancer elements,
or vectors that target integration into Rian, have a
very high chance of developing HCC, and in the
HCC, remnants of the vector will be likely be
present in Mir341. However, it needs to be em-
phasized that distinct, non-Mir341 rAAV integra-
tions within Rian do occur and appear pathogenic.
The results of the limited reanalysis of available
integration data presented in Table 2 confirms that
site preferences for rAAV do exist, especially when
one considers that some view a common integration
site (CIS) as a region of £30 kb that harbors two or
more integrations (the equivalent of ‡6.7 · 10-5
integration per base pair).54 Many more rAAV in-
tegrations must be captured and analyzed in order
to define rAAV CISs and to determine whether
sequence motifs, chromatin states/marks, and
vector characteristics influence integration pref-
erences. A recent publication describing a hybrid
AAV-piggyBac transposase delivery method might
also add important information about whether
AAV integration events can cause HCC.55
Another area of future experimental need sur-
rounds the precise characterization of rAAV inte-
gration events. A particularly relevant observation
is that both sides of the integration junction have
never been captured in any rAAV HCC study.
Thus, it remains possible that rAAV integration
might be associated with a complex rearrangement
or even translocation, in addition to the possibility
of vector concatamerization.56 Classical genomic
cloning, tiling, and/or new methods may need to be
Table 2. Genes that are frequent targets of rAAV integration from Chandler et al.50
Gene name
Unique HCC
integrations
Unique normal
liver integrations
Total number
of integrations in gene
Locus
size (bp)
Integration frequency
normalized to gene size
Mir341 (Rian) 18 3 21 96 2.19 · 10-1
AC152063.1 (Rian) 1 0 1 87 1.15 · 10-2
Mir212 0 1 1 91 1.10 · 10-2
Alb 68 75 143 15,715 9.10 · 10-3
Igfbp1 14 9 23 4,765 4.83 · 10-3
Gm14719 0 1 1 231 4.33 · 10-3
7SK 1 0 1 284 3.52 · 10-3
Afp 23 28 51 18,194 2.80 · 10-3
Gm16326 1 0 1 414 2.42 · 10-3
AY036118 0 1 1 725 1.38 · 10-3
Gm10800 1 0 1 755 1.32 · 10-3
Gm11620 2 0 2 1,845 1.08 · 10-3
Olfr1113 0 1 1 981 1.02 · 10-3
Dnajb8 0 1 1 989 1.01 · 10-3
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applied to elucidate fully the genomic features of
rAAV integration and whether they might con-
tribute to carcinogenesis.
A set of parallel studies should also be under-
taken, allowing the growing genomic resources
associated with human HCCs to be queried to as-
certain whether there is a recurrent set of genes,
RNAs, and/or regulatory elements commonly dys-
regulated in HCC. By integrating HTS-based an-
alyses of integrations in liver tissue from rodents
(and other species) treated with rAAV, an assess-
ment of genotoxic risk might be approximated by
simply mapping rAAV integrations, especially if
they fall into a CIS, onto a framework of genetic
elements that are associated with human HCC. A
pattern of vector integration into loci associated
with HCC, if seen in numerous samples from dif-
ferent animals, might indicate a potential hepatic
toxicity, and suggest further monitoring, such as
the assessment of circulating alpha-fetoprotein
and/or abdominal imaging, in clinical applications.
While the current safety profile of rAAV in
human clinical applications remains impeccable,
the preclinical animal model data, coupled with
an incomplete understanding of rAAV integra-
tion, should continue to motivate vector safety
studies in preclinical models using modern geno-
mic methods.
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